Apellis Pharmaceuticals, Inc. Shareholders' Equity for the year ending December 31, 2024: USD 228.54 M

Apellis Pharmaceuticals, Inc. Shareholders' Equity is USD 228.54 M for the year ending December 31, 2024, a 17.49% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Apellis Pharmaceuticals, Inc. Shareholders' Equity for the year ending December 31, 2023 was USD 194.52 M, a 14.51% change year over year.
  • Apellis Pharmaceuticals, Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 169.87 M, a -14.49% change year over year.
  • Apellis Pharmaceuticals, Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 198.66 M, a -2.88% change year over year.
  • Apellis Pharmaceuticals, Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 204.56 M.
Key Data
Date Shareholders' Equity Cash and Short-Term Investments Receivables Inventory